(OP: NYMXF )

0.0495 +0.0238 (+92.61%)

Streaming Delayed Price Updated: 1:53 PM EDT, Aug 19, 2024 Add to My Watchlist

Price and Volume

Volume	800
Open	0.0495
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0257
Today's Range	0.0495 - 0.0495
52wk Range	0.0001 - 1.400
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nymox Annual Report

July 18, 2024

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Required to Resubmit Application to DKMA

July 16, 2024

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Performance

YTD	-90.13%	-90.13%
1 Month	+395.00%	+395.00%
3 Month	-76.42%	-76.42%
6 Month	-87.93%	-87.93%
1 Year	-95.19%	-95.19%

More News

Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages

March 27, 2024

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox December 27 Message to Shareholders

December 27, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others

November 30, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court

November 21, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million

November 09, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized

November 03, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023

November 03, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations

November 02, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting

October 31, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting

October 27, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review

October 26, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH

September 25, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Reports Completion of $2 Million Private Placement

August 29, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox Announces $2 Million Private Placement

August 02, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Nymox's 3-month ex-CFO was Awarded an Unauthorized and Undisclosed Treasury Directive for 100,000 Shares of Nymox Stock Without the Knowledge or Approval of the Nymox Board or Nymox’s CEO

July 31, 2023

From Nymox Pharmaceutical Corporation

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.